Fundamental Analysis of JANUX THERAPEUTICS INC(NASDAQ:JANX) stock

Fundamental Rating

Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 570 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. JANX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

JANX had negative earnings in the past year.

JANX had a negative operating cash flow in the past year.

In the past 5 years JANX always reported negative net income.

In the past 5 years JANX always reported negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of -8.71%, JANX belongs to the best of the industry, outperforming 88.54% of the companies in the same industry.

JANX has a Return On Equity of -9.23%. This is amongst the best in the industry. JANX outperforms 91.01% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.71%
ROE	-9.23%
ROIC	N/A

ROA(3y)-13.75%

ROA(5y)-130.91%

ROE(3y)-15.17%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

JANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, JANX has more shares outstanding

JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

JANX has an Altman-Z score of 48.73. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.

JANX has a better Altman-Z score (48.73) than 97.71% of its industry peers.

JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	48.73

ROIC/WACCN/A

WACC10.42%

2.3 Liquidity

JANX has a Current Ratio of 38.80. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 38.80, JANX belongs to the top of the industry, outperforming 99.29% of the companies in the same industry.

JANX has a Quick Ratio of 38.80. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.

JANX has a better Quick ratio (38.80) than 99.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	38.8
Quick Ratio	38.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

JANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.95%, which is quite impressive.

JANX shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.88%.

EPS 1Y (TTM)20.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-104%

Revenue 1Y (TTM)53.88%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-82.56%

3.2 Future

JANX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.36% yearly.

Based on estimates for the next years, JANX will show a very strong growth in Revenue. The Revenue will grow by 83.20% on average per year.

EPS Next Y-2.17%

EPS Next 2Y-15.45%

EPS Next 3Y-16.46%

EPS Next 5Y-11.36%

Revenue Next Year71.62%

Revenue Next 2Y-40.39%

Revenue Next 3Y9.45%

Revenue Next 5Y83.2%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.

Also next year JANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -16.46% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-15.45%

EPS Next 3Y-16.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for JANX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

JANUX THERAPEUTICS INC

NASDAQ:JANX (12/4/2024, 8:00:02 PM)

After market: 66.8025 -0.03 (-0.05%)

66.835

+6.97 (+11.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.51B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.71%
ROE	-9.23%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	38.8
Quick Ratio	38.8
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)20.95%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-2.17%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)53.88%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

JANUX THERAPEUTICS INC (JANX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens